Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway

Figure 2

Effects of Mog and LPS on BV-2 cells and SH-SY5Y neurons viability. (a) BV-2 cells were treated with different concentrations (0, 0.125, 0.25, 0.5, 1, and 2 μg/mL) of LPS for 24 h and the cell viability was determined by MTT assay. (b) BV-2 cells were treated with different concentrations (0, 3.125, 6.25, 12.5, 25, and 50 μM) of Mog for 24 h and the cell viability was determined by MTT assay. (c) SH-SY5Y neurons were treated with Mog (0, 6.25, 12.5, and 25 μM) for 2 h followed by costimulation with LPS (0.5 μg/mL) for 18 h and the cell viability was determined by MTT assay. (d) BV-2 cells were treated with Mog (0, 6.25, 12.5, and 25 μM) for 2 h followed by treatment with LPS (0.5 μg/mL) for 18 h. Then, SH-SY5Y neurons were treated with the BV-2 cells-conditioned media for a further 24 h. The cell viability of SH-SY5Y neurons was examined by MTT assay. Similar results were obtained from three independent experiments. The values presented are the means ± SEM.  < 0.05 and  < 0.01 versus control group.

(a)

(b)

(c)

(d)